Evidence map›Paper›PMID 39998625›Full record

ArticleLung2025

Prevalence and Predictors of Response to Antifibrotics in Long-Term Survivors with Idiopathic Pulmonary Fibrosis.

Elisabetta Cocconcelli, Nicol Bernardinello, Paolo Cameli, Rosangela Di Liberti, Esam H Alhamad, Dario Gregori, Tommaso Pianigiani, Cristina Dartora, Riccardo Messina, Irene Di Leo and 6 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Journal of thoracic disease · 2026
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elisabetta CocconcelliRespiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova and Padova City Hospital, 35128, Padua, Italy.
Nicol BernardinelloRespiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova and Padova City Hospital, 35128, Padua, Italy.
Paolo CameliRespiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Rosangela Di LibertiDivision of Respiratory Medicine, Department PROMISE, "Paolo Giaccone" University Hospital, University of Palermo, Palermo, Italy.
Esam H AlhamadDepartment of Medicine, Division of Pulmonary Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Dario GregoriUnit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padua, Italy.
Tommaso PianigianiRespiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Cristina DartoraRespiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova and Padova City Hospital, 35128, Padua, Italy.
Riccardo MessinaDivision of Respiratory Medicine, Department PROMISE, "Paolo Giaccone" University Hospital, University of Palermo, Palermo, Italy.
Irene Di LeoDivision of Respiratory Medicine, Department PROMISE, "Paolo Giaccone" University Hospital, University of Palermo, Palermo, Italy.
Gioele CastelliRespiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova and Padova City Hospital, 35128, Padua, Italy.
Tiziana La BlascaDivision of Respiratory Medicine, Department PROMISE, "Paolo Giaccone" University Hospital, University of Palermo, Palermo, Italy.
Nicola ScichiloneDivision of Respiratory Medicine, Department PROMISE, "Paolo Giaccone" University Hospital, University of Palermo, Palermo, Italy.
Elena BargagliRespiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Paolo SpagnoloRespiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova and Padova City Hospital, 35128, Padua, Italy.
Elisabetta BalestroRespiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova and Padova City Hospital, 35128, Padua, Italy. elisabetta.balestro@aopd.veneto.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe natural history of IPF remains unpredictable despite antifibrotic treatment. In addition, some patients discontinue treatment due to the occurrence of adverse events. To date, no data exist on either the effect of long-term treatment or predictors of treatment response. In the present study, we aim to evaluate the functional trajectory of IPF patients treated with antifibrotics for at least three years and to establish predictors of treatment response.

methodsThis multicenter study enrolled long-term survivors IPF patients provided they had stopped treatment for no longer than one month during at least three-year study period. Based on the absolute decline of FVC%predicted (pred.) observed during the 3-year treatment and normalized per year, patients were defined as progressors (≥ 5%) or non-progressors (< 5%).

resultsWe identify 172 IPF patients who completed three years of antifibrotic treatment with no interruption. The 27% of these IPF patients progressed despite complete adherence to treatment. Progressors were more likely to be non-smokers compared to non-progressors, with higher occurrence of diarrhea and with a more preserved lung function at diagnosis. FVC %pred. and liters at diagnosis, a greater FVC decline in the 1-st year of follow up, being non-smokers, and complaining of diarrhea over treatment are independent predictors of progression.

conclusionAlmost one third of IPF patients adherent to three years of antifibrotics experience progression. A functional decline at first year of treatment despite preserved lung function at diagnosis, non-smoking status, and occurrence of diarrhea over treatment are independent predictors of disease progression.

Indexed as

Antifibrotic AgentsIdiopathic Pulmonary FibrosisLungAgedDiarrheaDisease ProgressionFemaleHumansMaleMiddle AgedPrevalenceSmokingSurvivorsTime FactorsTreatment OutcomeVital CapacityAntifibrotic AgentsInterstitial lung diseasesLung fibrosisRare lung diseases

Identifiers

PMID39998625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.